The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma.
The effects of anti-angiogenic therapies in guiding tumor angioarchitecture prompted us to examine the modifications in the vascular network of the oral squamous cell carcinoma (SCC) produced by the multitargeted tyrosine kinase inhibitor sunitinib malate. Twelve Syrian hamsters had their right buccal pouches submitted to tumor induction with dimethylbenzanthracene and carbamide peroxide for 55 days. The animals were then divided into two groups of six animals each; group I was treated with sunitinib malate and group II (control) was remained untreated. After 4 weeks, the hamsters had their vascular networks casted by Mercox® resin and analyzed by scanning electron microscopy. The qualitative study of the vascular network of the control tumor-bearing pouches showed images of intussusception and sprouting angiogenesis, flattened blood vessels, abrupt variations in their diameter, and a tortuous course. The samples treated with sunitinib exhibited a qualitative reduction of the signs of vascular proliferation. In addition, these casts presented an attenuation of the morphological features observed in the untreated tumor-bearing pouches. Quantitative analysis demonstrated that the pouches treated with sunitinib did not show a decrease (P > 0.05) in the vascular diameter and intervessel distances when compared with the control group. The results of the present study suggest that sunitinib may act on the vascular network of oral SCC, normalizing the blood vessels. However, further experiments should be performed in order to determine a judicious dose of this anti-angiogenic therapy.
Department of Surgery, Medical School, Pontifical Catholic University of Rio Grande do Sul, Av. Ipiranga, 6681, Porto Alegre/RS, CEP: 90619-900, Porto Alegre, Rio Grande do Sul, Brazil.
ViníCius Faccin
VF
Bampi
Carolina Ferreira
CF
Gomes
Laura Beatriz Oliveira
LB
De Oliveira
Jefferson Luis Braga
JL
Da Silva
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects* / Q000648:ultrastructure; D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D006224:Cricetinae; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008647:Mesocricetus; D008855:Microscopy, Electron, Scanning; D009062:Mouth Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic; D011758:Pyrroles / Q000008:administration & dosage*; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
DMBA; angiogenesis; corrosion casting; mesocricetus; scanning electron microscopy